Download Files:
Products Details
Product Description
– Etilevodopa (L-Dopa ethyl ester), an ethyl-ester proagent of Levodopa, is rapidly hydrolyzed to Levodopa and ethanol by nonspecific esterases in the gastrointestinal tract. Etilevodopa is used for the treatment of Parkinson disease (PD). Levodopa is the direct precursor of dopamine and is a suitable proagent as it facilitates CNS penetration and delivers dopamine[1][2][3].
Web ID
– HY-116016
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– Neuroscience-Neurodegeneration
Molecular Formula
– C11H15NO4
References
– [1]Djaldetti R, et al. Pharmacokinetics of etilevodopa compared to levodopa in patients with Parkinson’s disease: an open-label, randomized, crossover study. Clin Neuropharmacol. 2003 Nov-Dec;26(6):322-6.|[2]Blindauer K, et al. A randomized controlled trial of etilevodopa in patients with Parkinson disease who have motor fluctuations. Arch Neurol. 2006 Feb;63(2):210-6.|[3]Haddad F, et al. Dopamine and Levodopa Prodrugs for the Treatment of Parkinson’s Disease. Molecules. 2017 Dec 25;23(1). pii: E40.
CAS Number
– 37178-37-3
Molecular Weight
– 225.24
Compound Purity
– 97.0
SMILES
– N[C@H](C(OCC)=O)CC1=CC=C(C(O)=C1)O
Clinical Information
– Phase 3
Research Area
– Neurological Disease
Solubility
– 10 mM in DMSO
Target
– Dopamine Receptor;Drug Metabolite
Pathway
– GPCR/G Protein;Metabolic Enzyme/Protease;Neuronal Signaling
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
